Amgen (AMGN), UCB Announce Significant Data from Romosozumab Phase 3 in Osteoporosis
Go back to Amgen (AMGN), UCB Announce Significant Data from Romosozumab Phase 3 in Osteoporosis| Amgen Inc (NASDAQ: AMGN) | Delayed: 271.91 +2.98 (1.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $268.93 | 52 Week High | $176.85 | |||
| Open | $269.84 | 52 Week Low | $133.64 | |||
| Day High | $273.14 | P/E | 40.95 | |||
| Day Low | $269.84 | EPS | $6.64 | |||
| Volume | 2,165,656 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 64.93 +0.39 (0.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.54 | 52 Week High | $46.25 | |||
| Open | $65.55 | 52 Week Low | $32.74 | |||
| Day High | $65.55 | P/E | N/A | |||
| Day Low | $64.93 | EPS | $0.00 | |||
| Volume | 6,171 | |||||
